No annual revenue total was found in BOUNDLESS BIO, INC.'s SEC filings.
Boundless Bio, Inc. (BOLD) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$47.2 million. As of Jun 30, 2026 it held $72.6 million in cash and investments and $0 in total debt.
Revenue
—
Net income (TTM)
$-64.01M
+0.6% vs year-ago TTM
Operating cash flow (TTM)
$-56.25M
-1.9% vs year-ago TTM
Free cash flow (TTM)
$-56.73M
-0.9% vs year-ago TTM
EPS (TTM)
$-2.86
+1.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
22.41M
+0.5% vs prior year
Net cash
$72.63M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BOLD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1782303
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$63.6M | -$73.3M |
| Net income | -$58.2M | -$65.4M |
| Diluted EPS | -$2.60 | -$3.85 |
| Operating cash flow | -$46.7M | -$60.8M |
| Free cash flow | -$47.2M | -$63.4M |
| Total assets | $157.1M | $206.4M |
| Total liabilities | $58.4M | $55.8M |
| Stockholders' equity | $98.7M | $150.6M |
| Cash and investments | $107.6M | $152.1M |
| Total debt | $49.0M | $47.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
All 161 Boundless Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.